Author

L. Marchitto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 7 Research Focus:host-pathogen & immune response· 6 Research Focus:cell type annotation· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 2 Research Focus:clustering· 2 Research Focus:differential expression· 1

Frequent Co-Authors

A. Finzi· 7 shared G. Beaudoin-Bussieres· 6 shared H. Medjahed· 6 shared J. Richard· 6 shared C. Bourassa· 5 shared D. E. Kaufmann· 5 shared A. Tauzin· 4 shared C. Tremblay· 4 shared

Activity by Year

2021-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

A. Finzi

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity

L. Marchitto, J. Richard, J. Prevost, A. Tauzin, D. Yang, T.-J. Chiu, H.-C. Chen, M. A. Diaz-Salinas, M. Nayrac, M. Benlarbi, G. Beaudoin-Bussieres, S. P. Anand, K. Dionne, E. Belanger, D. Chatterjee, , A. Finzi

This paper combines three CD4-induced antibodies with a CD4-mimetic to achieve potent ADCC activity against HIV-1-infected cells.

bioRxiv · Jun 7, 2024Microbiology

CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies

J. Richard, G. Sannier, L. Zhu, J. Prevost, L. Marchitto, M. Benlarbi, G. Beaudoin-Bussieres, K. Hongil, Y. Sun, D. A. Chatterjee, H. Medjahed, C. Bourassa, G.-G. Delgado, M. Dube, F. Kirchhoff, , A. Finzi

The paper shows CD4 downregulation precedes Env expression in HIV-1-infected cells, making them resistant to non-neutralizing antibody-mediated ADCC.

bioRxiv · May 1, 2024Microbiology

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

G. Sannier, A. Nicolas, M. Dube, L. Marchitto, M. Nayrac, O. Tastet, A. Tauzin, R. Lima-Barbosa, M. Laporte, R. Cloutier, A. S. Flores, M. Boutin, S. Y. Gong, M. Benlarbi, S. Ding, , D. E. Kaufmann

bioRxiv · Sep 5, 2022Immunology

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

A. Laumaea, L. Marchitto, G. Beaudoin-Bussieres, S. Ding, R. Gasser, D. Chatterjee, G. Gendron-Lepage, H. Medjahed, H.-C. Chen, A. B. Smith, H. Ding, J. C. Kappes, B. H. Hahn, F. Kirchhoff, J. Richard, , A. Finzi

The paper shows that small CD4 mimetics expose ADCC epitopes on HIV-1-infected macrophages, making them susceptible to antibody-dependent cellular cytotoxicity.

bioRxiv · Jun 30, 2022Microbiology

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

D. Chatterjee, A. Tauzin, L. Marchitto, S. Y. Gong, M. Boutin, C. Bourassa, G. Beaudoin-Bussieres, Y. Bo, S. Ding, A. Laumaea, D. Vezina, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, , A. Finzi

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

bioRxiv · Dec 21, 2021Microbiology

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, , D. E. Kaufmann

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

bioRxiv · Dec 18, 2021Immunology

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

Y. Chen, L. Sun, I. Ullah, G. Beaudoin-Bussieres, S. P. Anand, A. P. Hederman, W. D. Tolbert, R. Sherburn, D. N. Nguyen, L. Marchitto, S. Ding, D. Wu, Y. Luo, S. Gottumukkala, S. Moran, , M. Pazgier

The paper develops ACE2-Fc molecules that neutralize SARS-CoV-2 and show Fc-effector activity, effectively treating lethal infection in mice.

bioRxiv · Nov 24, 2021Microbiology

Covid-19 vaccine immunogenicity in people living with HIV-1

L. Nault, L. Marchitto, G. Goyette, D. Tremblay-Sher, C. Fortin, V. Martel-Laferriere, B. Trottier, J. Richard, M. Durand, D. E. Kaufmann, A. Finzi, C. Tremblay

This study evaluates mRNA vaccine immunogenicity in HIV-positive individuals, finding similar anti-RBD IgG responses to controls in those with CD4 counts >250 cells/mm3, but significantly lower responses in those with <250 cells/mm3.

bioRxiv · Aug 13, 2021Immunology